Turnstone Biologics Corp (TSBX) Return on Investment ROI from the second quarter of 2025 to second quarter of 2024 and for the year 2025, average high and low, overall ranking from Jun 30 2025 to Jun 30 2024 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Turnstone Biologics Corp   (NASDAQ: TSBX)


Turnstone Biologics's ROI from its second quarter of 2025 to the second quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Turnstone Biologics's ROI in the second quarter of 2025?
Turnstone Biologics Corp recorded a cumulative net loss of $-47 million during 12 months ending in the second quarter of 2025, resulting in a negative return on investment (ROI) of -167.08%.

Within the Healthcare sector 785 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2025 from 3850 to 4263.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter		 (Sep 30 2024)
III. Quarter		 (Jun 30 2024)
II. Quarter
Y / Y Investment Change TTM -68.79 % -55.43 % -36.94 % 16.56 % 179.75 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 15 21 32 45 61
Return On Investment (TTM) -167.08 % -158.46 % -128.93 % -103.11 % -82.53 %
TSBX's Overall Ranking # 4263 # 3850 # 3836 # 2849 # 3202
Seq. Investment Change TTM -28.96 % -27.62 % -23.87 % -20.27 % 1.44 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -47 -63 -71 -74 -75

TSBX Company Profile >> Back to TSBX Roi Comparisons >> See Annual TSBX Return On Investment



Return On Investment TSBX's Ranking
Within: No.
Industry # 130
Sector # 786
Overall # 4263

Return On Investment Statistics
High Average Low
-21.47 %
-96.82 %
-167.08 %
(Jun 30 2024)   (Jun 30 2025)



  News about Turnstone Biologics Corp Return on Investment ROI

Turnstone Biologics Appoints Biotech Veteran to Board of Directors as Company Recovers from Financial Setback

April 16, 2024



Turnstone Biologics Corp, a leading biotechnology firm, has recently made an important addition to its Board of Directors by appointing industry veteran William Waddill. This move comes at a crucial time for the company, as it aims to recover from recent financial challenges. Despite recording a significant net loss during the previous fiscal year, Turnstone Biologics remains optimistic, with a promising 23.17% surge in their market performance in 2024.
Turnstone Biologics Welcomes William Waddill:
Recognizing the necessity for new leadership and expertise, Turnstone Biologics has appointed William Waddill to its esteemed Board of Directors. Waddill s extensive experience in the biotechnology sector not only strengthens the company s governance but also instills renewed confidence among shareholders and investors. With his deep understanding of the industry s dynamics, Waddill is poised to contribute significantly to Turnstone Biologics growth strategy and overall corporate development.

Triumph through Trials: Turnstone Biologics Resiliently Forging Ahead in Healthcare Innovation

February 20, 2024



In a recent press release, Turnstone Biologics, a leading biotechnology company, sadly announced the passing of their esteemed Chief Legal Officer, P. Joseph Campisi, Jr., Esq., after a long and courageous battle with cancer. While mourning this profound loss, Turnstone is resolute in their mission to revolutionize the healthcare sector. Additionally, amid challenging financial circumstances, Turnstone Biologics has emerged as a beacon of profitability with remarkable returns on investment.
Facts:
1. Chief Legal Officer s Passing:
Turnstone Biologics announced with great sadness that P. Joseph Campisi, Jr., Esq., Chief Legal Officer of the company, has passed away following a prolonged battle with cancer. Campisi s contributions to the company were invaluable, and his loss will be deeply felt by the entire Turnstone family.





Financial Statements
Turnstone Biologics's II. Quarter Investments $ 15 Millions TSBX's Balance sheet
Turnstone Biologics's II. Quarter Income $ -5 Millions Quarterly TSBX's Income Statement
TSBX's Income by Division See TSBX's Income by Division


TSBX Annual Return On Investment (Dec 31 2024)
2024		 (Dec 31 2023)
2023


Total Investments in Millions 32 101 0 0 0
Y / Y Investment Growth -68.33 % - - - -
Net Income in Millions -71 -55 0 0 0
Y / Y Net Income Growth - - - - -
Annual Return On Investment -221.78 % -54.74 % - - -


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
TSBX's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for TSBX's Competitors
Subscribers only: Roi for Turnstone Biologics's Suppliers
Subscribers only: Return On Investment for TSBX's Customers

Other Ratios
TSBX's Roa TSBX's Inventory Turnover Ratio TSBX's Growth Rates TSBX's Dividend Statistics
TSBX's Profitability Ratios TSBX's Asset Turnover Ratio TSBX's Dividend Growth
TSBX's Roe TSBX's Valuation Ratios TSBX's Financial Strength Ratios TSBX's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2025, within Healthcare Sector ROI

Date modified: 2026-08-29T17:48:16+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.